Brian Halak

Bio

Brian joined Domain in 2001 and became a partner in 2006. He has been involved with new company creation and investments in all sectors in which Domain invests. He also established and directed Domain’s prior initiative in China in collaboration with Beijing Elite. Present board memberships include Alimera Sciences, Kona Medical and Nobias Therapeutics. He previously served on the boards of BioNano Genomics, Eddingpharm, Esprit Pharma (until acquired by Allergan), GI Dynamics, Tobira Therapeutics, Vanda Pharmaceuticals and WindMIL Therapeutics. Prior to Domain, Brian was an associate with Advanced Technology Ventures where he participated in the firm’s investments in Plexxikon, Percardia and Emphasys. Previous to that, he was a consultant at the Wilkerson Group, where he developed strategy for pharmaceutical and medical device companies. Brian received his BSE in bioengineering from University of Pennsylvania and his Ph.D. in immunology from Thomas Jefferson University. Brian is currently a member of the Advisory Board for the Department of BioEngineering of the University of Pennsylvania, an advisor to Elm Street Ventures, and a director on the board of Life Sciences Pennsylvania.